GreenSignal Bio Pharma IPO


Greensignal Bio Pharma Logo

GreenSignal Bio Pharma Ltd (GSBPL) is an Indian vaccine manufacturing company with global operations. The Chennai-based company manufactures two products:

  1. BCG Vaccine for immunization against Tuberculosis
  2. BCG-ONCO for Immunotherapy (Freeze Dried) BP for the treatment of Urinary Bladder Carcinoma and the brand name for the same is ‘Urovac’.

The company is one of the four companies globally which have been WHO-prequalified to supply the BCG vaccine to UNICEF. The company has secured a long term arrangement since November 2015 to supply the BCG vaccine to UNICEF. GSBPL also supplies the BCG vaccine to the Ministry of Health, India pursuant to the tendering process. The company has been successful in obtaining bids for the years 2009-2010, 2010-2011, 2011-12, 2012-13and 2015-2016. It also supplies the BCG vaccine to Indonesia, and Nepal which are countries outside the UNICEF ambit.

Its BCG-ONCO for Immunotherapy drug is distributed throughout India vide commercial arrangements in India and we intend to market this immunotherapy drug in overseas jurisdictions as well. Presently, the company has made several limited supplies to various countries such Lebanon, Saudi Arabia, Turkey and Switzerland.

GreenSignal Bio Pharma’s business is organized into domestic (i.e. Indian) and international operations. For fiscal year 2016, its domestic and international operations accounted for 53.8% and 46.2%, respectively, of its net revenues from operations. The standalone net revenues from operations for the period ended 30 June 2016 was INR10.14 crore and for the years ended 31 March 2016 was INR20.38 crore, respectively. The company’s consolidated net revenues from operations grew at a CAGR of 210.7% in the period from fiscal year 2015 to fiscal year 2016.

GreenSignal Bio Pharma has a manufacturing facility located at Pappankuppam Village, Gummidipoondi, Tiruvallur District, Tamil Nadu equipped with advanced equipment dedicated for the manufacturing of live attenuated BCG Vaccine and the BCG-ONCO for immunotherapy.

Promoter of GreenSignal Bio Pharma: P Sundaraparipooranan and P Murali

GreenSignal Bio Pharma IPO details
Subscription Dates 9 – 22 November 2016 (Issue withdrawn due to poor response)
Price Band INR68 – 76 per share (Revised from INR76 – 80 per share)
Fresh issue NIL
Offer For Sale 14,579,560 shares (INR116.63 crore at upper price band)
Total IPO size 14,579,560 shares (INR116.63 crore at upper price band)
Minimum bid (lot size) 175 shares
Face Value  INR10 per share
Retail Allocation 10%
Listing On BSE, NSE


GreenSignal Bio Pharma’s consolidated financial performance (in INR crore)

  FY2012 FY2013 FY2014 FY2015 FY2016
Total revenue 11.26 11.69 3.52 6.60 20.49
Total expenses 11.31 11.86 4.58 6.61 13.55
Profit after tax -0.48 -0.50 -1.29 -0.21 5.30

GreenSignal Bio Pharma Ltd 
13/A-3, Sai Niketan, Circular Road,
United India Colony, Kodambakkam, Chennai 600024

Phone: +91 44 2472 2244
Fax: +91 33 2472 2233
Email: [email protected]

Bigshare Services Private Ltd 
E2, Ansa Industrial Estate, Sakivihar Road,
Sakinaka, Andheri East, Mumbai – 400 072
Maharashtra, India

Phone: +91 22 40430200
Fax: +91 22 28475207
[email protected]

GreenSignal Bio Pharma IPO Subscription Details


Subscription (no. of times, at 5 PM) 

Day 1

Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8

Day 9



0.00 0.00 0.00 0.00 0.00 0.00  0.20  0.20


0.02 0.12 0.12 0.12 1.16 1.16  0.13  0.13


1.58 7.96 8.73 8.74 8.90 8.83  8.58  8.46


0.16 0.81 0.89 0.89 1.06 1.05 1.03


GreenSignal Bio Pharma IPO allotment status will be available on Bigshare’s website. Click on this link to get allotment status.

IPO Opening Date: 9 November 2016

IPO Closing Date: 22 November 2016 (Issue withdrawn due to poor response)

Finalisation of Basis of Allotment:

Initiation of refunds:

Transfer of shares to demat accounts:

Listing Date:

Listing Price on NSE:

Closing Price on NSE:


  1. My broker is not accepting grey market applications in Green signal. Surprising coz the issue looks good to me. It has good demand in the market. Broker saying it is because of 10% in retail category.

  2. Boarders, stay away from Greensignal ipo. The promoter family has political connections which is how it got the unicef contract. It is simply to get the most out of the bull market. Just two contracts and promoters looking to sell shares, nt good for small investors..

  3. I would strongly recommend a ‘BUY’. In stocks past performance serves little purpose beyond establishing the legitimacy of a company. Stock market is largely a forward looking tool and this is where GreenSignal Bio Pharma scores with a strong pipeline. I observed some comments on ‘Political Connection’. These are silly. UNICEF & WHO are not institutions that will sabotage their reputation. I am positive about this stock.

    • Haha, your comments are laughable Sneha. You are using stuff from articles on this site to make a logic for investing in Greensignal. May be you can come up with something more meaningful next time…

  4. By RM at IIFL says Laurus and Eris are much better than Green Signal with proven business model. just waiting for these ipos…

    • Yes, the extension is a great opportunity to cancel applications but retail investors just don’t learn. They remain small because of this.

  5. Boarders please help me I want to cancel my application in this IPO. I have been trying to cancel my bid on Andhra bank internet banking but not able to do that as the system logs me out in just 2 mins. I spend 2 hour on their hlpline but no result. Anyone else facing this issue please help.

    • Hi Kalyan, what Viraj is saying is a sure-shot way but you have one more day and should contact your bank first and then registrar. Greensignal is not such a good company and the market is too dangerous now. Best to cancel the application.

  6. Bottomline for retail investors is clear that Greensignal has lost its chance. They should withdraw this dud instead of extending again and again. Even if they get a deal with institutions to get subscription, it will trap small investors.


Please enter your comment!
Please enter your name here